With with GLP-1 drugs, gastrointestinal issues, such as nausea, vomiting, constipation, and gastroesophageal reflux disease, ...

Learn how diabetes medications could revolutionize stroke prevention and enhance heart and brain health with breakthrough ...

Websites that sell compounded glucagon-like peptide-1 receptor agonists often partially inform or misinform consumers.

For people with diabetes, the use of GLP-1 RAs is associated with reduced risk for certain disorders and conditions.

With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...

The San Diego–based company’s molecules avoid the well-trod GLP-1 pathway in favor of an alternate route in the gut.

GLP-1 agonist initiators had a significantly higher likelihood of undergoing thyroid ultrasonography at 6 and 12 months, ...

Adults with type 2 diabetes using a GLP-1 drug have a similar risk for thyroid cancer as those using other diabetes drugs, though increased thyroid cancer risk was observed in the first year after GLP ...

HealthDay News — Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the short term, according to a study published online January ...

The study of more than two million veterans with diabetes details GLP-1 RA use relating to 175 outcomes; without ...

Health-care companies rose after more promising data for the best-selling Glucagon-like Peptide inhibitor drugs. Shares of Novo Nordisk and Eli Lilly, the two leading producers of GLP-1 drugs, rallied ...

Computational research conducted by scientists from Washington University in St. Louis shows that GLP-1 agonists can have ...